Akoya Biosciences Inc

NASDAQ AKYA

Download Data

Akoya Biosciences Inc Gross Working Capital 1 year YoY Change (%) for the year ending December 31, 2023: 16.06%

Akoya Biosciences Inc Gross Working Capital 1 year YoY Change (%) is 16.06% for the year ending December 31, 2023, a 143.83% change year over year. Gross working capital is a financial metric that represents the amount of a company's current assets available to cover its current liabilities and short-term debt obligations. It is calculated by subtracting the sum of current liabilities and short-term debt from the total current assets of a company. Gross working capital provides insights into a company's short-term liquidity and its ability to meet its financial obligations in the near future. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Akoya Biosciences Inc Gross Working Capital for the year ending December 31, 2022 was USD 71.51 M, a -36.64% change year over year.
  • Akoya Biosciences Inc Gross Working Capital for the year ending December 31, 2021 was USD 112.86 M, a 995.20% change year over year.
  • Akoya Biosciences Inc Gross Working Capital for the year ending December 31, 2020 was USD 10.30 M, a -47.53% change year over year.
  • Akoya Biosciences Inc Gross Working Capital for the year ending December 31, 2019 was USD 19.64 M.
NASDAQ: AKYA

Akoya Biosciences Inc

CEO Mr. Brian McKelligon
IPO Date April 16, 2021
Location United States
Headquarters 100 Campus Drive, Marlborough, MA, United States, 01752
Employees 330
Sector Healthcare
Industry Medical instruments & supplies
Description

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

PDEX

Pro-Dex Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email